アフェレシス：市場洞察・競合環境・市場予測 (～2030年)

アフェレシスの市場規模は、2023年の22億3,066万米ドルから、予測期間中はCAGR 8.75%で推移し、2030年には36億7,155万米ドルの規模に成長すると予測されています。

免疫性血小板減少症 (ITP) や血友病のような慢性疾患の有病率の増加、製品開発活動の活発化、バイオ製薬会社による原血漿の需要増加が、予測期間中の市場全体の成長に寄与する見通しです。

アフェレシス：市場力学

2022年のNational Organization for Rare Disordersによると、免疫性血小板減少症 (ITP) は3カ月の乳児から100歳以上の高齢者まで、あらゆる年齢層の人が罹患する可能性があると報告されています。ITPと診断された患者の約40％は10歳未満の小児です。世界的には、20万人以上がこの疾患に罹患していると推定されています。

World Federation of Haemophilia (2022年) の報告によると、世界中で毎年約20,000人が血友病を発症しており、そのうち約7,000人が重症に分類されています。また、血友病の患者数は23万3,577人であり、その内訳は血友病Aが18万5,318人、血友病Bが3万7,998人であるとしています。

免疫性血小板減少症 (ITP) や血友病のような慢性血液疾患の有病率の増加は、アフェレシスを含む高度な治療オプションの需要を促進しています。アフェレシスは、血液成分の標的を絞った除去や置換を行うため、出血性合併症や免疫機能障害を管理し、患者の転帰を改善するための貴重な治療法です。さらに、凝固因子へのアクセスにおける世界の格差は、アフェレシスのような代替治療法の必要性を示しており、市場の可能性をさらに拡大させています。

地域別では、北米地域が大きな収益シェアを占めると推計されています。これは、癌やギランバレー症候群 (GBS) の患者数の増加、継続的な製品開発戦略、改善された治療機能と効率の提供など、いくつかの要因によるものと考えられています。

当レポートでは、世界のアフェレシスの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 アフェレシス市場レポート：イントロダクション

• 調査範囲
• 市場の分類
• 市場の想定

第2章 アフェレシス市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 アフェレシス市場：主要要因分析

• 市場促進要因
  • 慢性疾患の罹患率の増加
  • 世界中で製品開発活動が増加
  • バイオ医薬品企業からの原料血漿の需要増加
• 市場抑制要因と課題
  • アフェレシスプロセスの高いコスト
  • アフェレシスプロセスに伴うリスク
• 市場機会
  • 小児向けに特別に設計された新しいアフェレシス治療法の革新と研究開発の急増
  • リポタンパク質成分除去療法のコスト削減と治療法の普及

第6章 アフェレシス市場：ポーターのファイブフォース分析

第7章 アフェレシス市場の評価

• 製品タイプ別
  • アフェレシス装置
  • ディスポーザブル
• 技術別
  • 遠心分離
  • 膜ろ過
• 処置別
  • 白血球除去療法
  • 血漿交換
  • 血小板成分採取
  • 赤血球除去療法
  • その他
• 用途別
  • 腎疾患
  • 血液疾患
  • 神経疾患
  • 自己免疫疾患
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 アフェレシス市場：企業・製品プロファイル

• B. Braun Melsungen AG
• Asahi Kasei Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Terumo Corporation
• Baxter
• Kaneka Corporation
• Sumitomo Bakelite Company Limited
• Medica SPA
• Nikkiso Co., Ltd.
• Cerus Corporation
• Miltenyi Biotec B.V. & Co. KG
• Haier Inc.
• Otsuka Holdings

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Apheresis Market in Global (2021-2030)
• Table 3: Apheresis Market in Global by Product Type (2021-2030)
• Table 4: Apheresis Market in Global by Technology (2021-2030)
• Table 5: Apheresis Market in Global by Procedure (2021-2030)
• Table 6: Apheresis Market in Global by Application (2021-2030)
• Table 7: Apheresis Market in Global by Geography (2021-2030)
• Table 8: Apheresis Market in North America (2021-2030)
• Table 9: Apheresis Market in the United States (2021-2030)
• Table 10: Apheresis Market in Canada (2021-2030)
• Table 11: Apheresis Market in Mexico (2021-2030)
• Table 12: Apheresis Market in Europe (2021-2030)
• Table 13: Apheresis Market in France (2021-2030)
• Table 14: Apheresis Market in Germany (2021-2030)
• Table 15: Apheresis Market in United Kingdom (2021-2030)
• Table 16: Apheresis Market in Italy (2021-2030)
• Table 17: Apheresis Market in Spain (2021-2030)
• Table 18: Apheresis Market in the Rest of Europe (2021-2030)
• Table 19: Apheresis Market in Asia-Pacific (2021-2030)
• Table 20: Apheresis Market in China (2021-2030)
• Table 21: Apheresis Market in Japan (2021-2030)
• Table 22: Apheresis Market in India (2021-2030)
• Table 23: Apheresis Market in Australia (2021-2030)
• Table 24: Apheresis Market in South Korea (2021-2030)
• Table 25: Apheresis Market in Rest of Asia-Pacific (2021-2030)
• Table 26: Apheresis Market in the Rest of the World (2021-2030)
• Table 27: Apheresis Market in the Middle East (2021-2030)
• Table 28: Apheresis Market in Africa (2021-2030)
• Table 29: Apheresis Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Apheresis Market in Global (2021-2030)
• Figure 3: Apheresis Market in Global by Product Type (2021-2030)
• Figure 4: Apheresis Market in Global by Technology (2021-2030)
• Figure 5: Apheresis Market in Global by Procedure (2021-2030)
• Figure 6: Apheresis Market in Global by Application (2021-2030)
• Figure 7: Apheresis Market in Global by Geography (2021-2030)
• Figure 8: Apheresis Market in North America (2021-2030)
• Figure 9: Apheresis Market in the United States (2021-2030)
• Figure 10: Apheresis Market in Canada (2021-2030)
• Figure 11: Apheresis Market in Mexico (2021-2030)
• Figure 12: Apheresis Market in Europe (2021-2030)
• Figure 13: Apheresis Market in France (2021-2030)
• Figure 14: Apheresis Market in Germany (2021-2030)
• Figure 15: Apheresis Market in United Kingdom (2021-2030)
• Figure 16: Apheresis Market in Italy (2021-2030)
• Figure 17: Apheresis Market in Spain (2021-2030)
• Figure 18: Apheresis Market in the Rest of Europe (2021-2030)
• Figure 19: Apheresis Market in Asia-Pacific (2021-2030)
• Figure 20: Apheresis Market in China (2021-2030)
• Figure 21: Apheresis Market in Japan (2021-2030)
• Figure 22: Apheresis Market in India (2021-2030)
• Figure 23: Apheresis Market in Australia (2021-2030)
• Figure 24: Apheresis Market in South Korea (2021-2030)
• Figure 25: Apheresis Market in Rest of Asia-Pacific (2021-2030)
• Figure 26: Apheresis Market in the Rest of the World (2021-2030)
• Figure 27: Apheresis Market in the Middle East (2021-2030)
• Figure 28: Apheresis Market in Africa (2021-2030)
• Figure 29: Apheresis Market in South America (2021-2030)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing prevalence of chronic disorders and increasing product developmental activities around the world

The apheresis market was valued at USD 2,230.66 million in 2023 and is estimated to grow at a CAGR of 8.75% during the forecast period from 2024 to 2030 to reach USD 3,671.55 million by 2030. The market is experiencing significant growth due to the increasing prevalence of different types of chronic disorders like immune thrombocytopenia (ITP) and hemophilia among the population, rising product developmental activities, and rising demand for source plasma from biopharmaceutical companies acting as major factors contributing to the overall growth of the apheresis market during the forecast period from 2024 to 2030.

Apheresis Market Dynamics:

The National Organization for Rare Disorders in 2022, stated that immune thrombocytopenia (ITP) can affect individuals of all ages, ranging from as young as 3 months to over 100 years old. Approximately 40% of those diagnosed with ITP are children under the age of 10. Globally, it is estimated that more than 200,000 people are affected by this condition.

According to the World Federation of Haemophilia (2022) reports, approximately 20,000 people with hemophilia are born each year worldwide, with about 7,000 of these cases being classified as severe. In addition to this, the source further stated that there are 233,577 individuals with hemophilia, comprising 185,318 with Hemophilia A and 37,998 with Hemophilia B.

The rising prevalence of chronic hematological disorders like immune thrombocytopenia (ITP) and hemophilia is driving the demand for advanced treatment options, including apheresis. Apheresis offers targeted removal or replacement of blood components, making it a valuable therapy for managing bleeding complications, immune dysfunction, and improving patient outcomes. Additionally, the global disparities in access to clotting factors highlight the need for alternative therapeutic modalities like apheresis, further expanding its market potential.

Various product development activities by key market players will further boost the market for the same. For instance, in May 2021, Baxter International Inc. announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).

Hence, the interplay of all the above-mentioned factors is expected to drive the apheresis market during the given forecast period from 2024 to 2030.

However, the high cost involved in the apheresis process, risks associated with the apheresis process, and others may restrict the market growth for the apheresis market.

Apheresis Market Segment Analysis:

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the apheresis market, the disposables category is expected to have a significant revenue share in the year 2023. This can be attributed to the increased consumption of disposables in the process of apheresis.

The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21(R) and LIFE 18(TM) apheresis unit's disposables from Miltenyi Biotec, the disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies to build and flourish their market for apheresis.

Therefore, the widespread uses and various advantages of the disposables category that enhance performance and usability, solidify a significant impact on the growth of the overall apheresis market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall apheresis market:

Among all the regions, North America is estimated to hold a significant revenue share in the apheresis market. This can be attributed to several factors such as rising cancer cases and Guillain-Barre Syndrome (GBS), continuous product developmental strategies by regulatory bodies, that offer improved treatment features and efficiency, that act as key factors contributing to the growth of the apheresis market in the North America region during the forecast period from 2024 to 2030.

As per figures directed by the Globocan 2024, it indicated that in the year 2022 Leukemia affected 63,144 people in the US, whereas in Canada leukemia affected about 8,503 people. The same source also mentioned that by the year 2045, leukemia will afflict about 101 thousand people in the North America region. As leukemia cases rise, apheresis is increasingly utilized for managing complications like hyperleukocytosis and for collecting stem cells for transplants and thereby the market for the same is increased.

According to data from the Centers for Disease Control and Prevention (2023), it stated that Guillain-Barre Syndrome (GBS) is a rare disorder in which the body's immune system mistakenly attacks the peripheral nerves. This damage to the nerves leads to muscle weakness and, in some cases, paralysis. The exact cause of GBS is not fully understood, but it frequently occurs following an infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. Apheresis plays a critical role in treating autoimmune disorders like Guillain-Barre Syndrome by removing harmful antibodies. Thus the rising clinical reliance highlights the expanding market for apheresis systems and services.

Various product developmental strategies such as clearances by regulatory authorities in the region play a major role in pushing forward the revenue shares of apheresis. For example, in August 2023, Terumo Blood and Cell Technologies (Terumo BCT) announced the U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle.

Moreover, product launches by key market players in the region are further expected to propel the growth of the North America apheresis market.

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the apheresis market during the forecast period from 2024 to 2030.

Apheresis Market key players:

Some of the key market players operating in the apheresis market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V. & Co. KG, Haier Inc., Otsuka Holdings, and others.

Recent Developmental Activities in the Apheresis Market:

• In September 2023, Sanguine Biosciences (Sanguine), a leader in connecting patients with biomedical researchers to accelerate precision medicine R&D, announced the opening of a blood donor center in Los Angeles. The center specialized in collecting concentrated white blood cell biospecimens through apheresis.
• In June 2022, Terumo Blood and Cell Technologies, a medical technology company specializing in products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, announced that NHS England selected the automated red blood cell exchange (RBCX) procedure, performed using the company's Spectra Optia(R) Apheresis System, through the NHS MedTech Funding Mandate (MTFM) for treating sickle cell disease.

Key takeaways from the Apheresis market report study

• Market size analysis for current apheresis market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the apheresis market
• Various opportunities available for the other competitors in the apheresis market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current apheresis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?

Target audience who can be benefited from this Apheresis market report study

• Apheresis device providers
• Research organizations and consulting companies
• Apheresis-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in apheresis
• Various end-users who want to know more about the apheresis market and the latest developments in the apheresis market

Frequently Asked Questions for the Apheresis Market:

1. What are apheresis?

• The apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).

2. What is the market for apheresis?

• The apheresis market was valued at USD 2,230.66 million in 2023 and is estimated to grow at a CAGR of 8.75% during the forecast period from 2024 to 2030 to reach USD 3,671.55 million by 2030.

3. What are the drivers for the apheresis market?

• The market is experiencing significant growth due to the increasing prevalence of different types of chronic disorders like immune thrombocytopenia (ITP) and hemophilia among the population, rising product developmental activities, and rising demand for source plasma from biopharmaceutical companies that are acting as major factors contributing to the overall growth of the apheresis market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the apheresis market?

• Some of the major market players operating in the apheresis market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V. & Co. KG, Haier Inc., Otsuka Holdings, and others.

5. Which region has the highest share in the apheresis market?

• Among all the regions, North America is estimated to hold a significant revenue share in the apheresis market. This can be attributed to several factors such as rising cancer cases and Guillain-Barre Syndrome (GBS), continuous product developmental strategies by regulatory bodies, that offer improved treatment features and efficiency, which are the major key factors that contribute to the growth of the apheresis market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Apheresis Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Apheresis Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Apheresis Market Key Factors Analysis

• 5.1. Apheresis Market Drivers
  • 5.1.1. Increasing prevalence of chronic disorders
  • 5.1.2. Increasing product developmental activities around the world
  • 5.1.3. Rising demand for source plasma from biopharmaceutical companies
• 5.2. Apheresis Market Restraints and Challenges
  • 5.2.1. High cost involved in the apheresis process
  • 5.2.2. Risks associated with the apheresis process
• 5.3. Apheresis Market Opportunities
  • 5.3.1. Surge in innovation and R&D for new apheresis treatment methods specially designed for children
  • 5.3.2. Reduction in the cost of lipoprotein apheresis and widespread availability of the therapy

6. Apheresis Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Apheresis Market Assessment

• 7.1. By Product Type
  • 7.1.1. Apheresis machines
  • 7.1.2. Disposables
• 7.2. By Technology
  • 7.2.1. Centrifugation
  • 7.2.2. Membrane filtration
• 7.3. By Procedure
  • 7.3.1. Leukapheresis
  • 7.3.2. Plasmapheresis
  • 7.3.3. Plateletpheresis
  • 7.3.4. Erythrocytapheresis
  • 7.3.5. Others
• 7.4. By Application
  • 7.4.1. Renal Disorders
  • 7.4.2. Hematological Disorders
  • 7.4.3. Neurological Disorders
  • 7.4.4. Autoimmune Disorders
  • 7.4.5. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Apheresis Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Apheresis Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Apheresis Market Size in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Apheresis market size in USD million (2021-2030)
    • 7.5.2.5. Spain Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Apheresis Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.3. India Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Apheresis Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Apheresis Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Apheresis Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Apheresis Market Size in USD million (2021-2030)

8. Apheresis Market Company and Product Profiles

• 8.1. B. Braun Melsungen AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Asahi Kasei Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Fresenius Kabi AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Haemonetics Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Terumo Corporation
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Baxter
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Kaneka Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Sumitomo Bakelite Company Limited
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Medica SPA
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Nikkiso Co., Ltd.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cerus Corporation
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Miltenyi Biotec B.V. & Co. KG
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Haier Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Otsuka Holdings
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us